Most tri-county stocks gain along with indices
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →The Trade Desk soars after beating analyst estimates
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Tri-county stocks mixed as national indices rise
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Sientra misses earnings estimates as net loss grows
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Tri-county stocks mixed but most biotechs gain
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Inphi, Atara and Limoneira stocks have big gains
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen’s Otezla could be treatment for COVID-19
Amgen’s newly acquired Otezla product line could find a role in a suite of new therapies designed to treat COVID-19 patients. News of the potential for the rheumatoid arthritis product came as the Thousand Oaks-based biotech reported that earnings and revenue shot up in the first quarter. The company’s outlook stayed flat as it shifts Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
